Helping people live well longer.
Klotho Therapeutics, Inc., (KTI) is a privately held biotechnology company developing modified recombinant versions of the human protein Klotho that has shown great potential to delay diseases of aging and improve longevity.
Klotho Team has 250+ Years Pharma Experience, 500+ Clinical Trials, including 60+ drug Approvals including numerous Blockbuster Drugs
The company builds upon the $200+ million previously invested in Klotho research that demonstrates how Klotho, a naturally occurring protein in humans and animals, can positively impact aging, cognition, kidney function, fibrosis, and cancer. KTI has worldwide patents on Klotho proteins.
KTI is well positioned to enter human trials within 12 months focused on its first indication: to slow the progression of kidney failure, which affects up to 40 million patients in the US per year, with over 600,000 currently on dialysis. Kidney disease represents a multi-billion-dollar market opportunity in the U.S. alone.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2016
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Klotho Therapeutics, Inc. founded?
Klotho Therapeutics, Inc. was founded in 2016.
What industry is Klotho Therapeutics, Inc. in?
Klotho Therapeutics, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Klotho Therapeutics, Inc. based?
Klotho Therapeutics, Inc. is headquartered in San Diego, United States.
Find investors for your startup like Klotho Therapeutics, Inc.
Gritt sends AI-personalised outreach to each investor — from your Gmail
